NCT01244139View on ClinicalTrials.gov

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

PHASE1CompletedINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions

Relapsing-Remitting Multiple SclerosisMultiple Sclerosis

Interventions

DRUG

BIIB033

IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg

DRUG

Placebo

IV infusion dummy drug

Trial Locations (1)

Unknown

Research Site, Centennial

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Biogen

INDUSTRY